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Summary Introduction: Testicular tumors in children have two peaks with different types of 
tumors; in the first 4 years of life a third to half are benign with increased risk of malignancy 
during puberty. The pathology of testicular tumors between these peaks, at the age of 5 to 12 
years, is not known. We hypothesized that because of the low level of testosterone at this 
time, the incidence of malignant tumors is very low. 
Objective: To compare malignancy risk of primary testicular tumors in children in the 
prepubertal period (5–12 years) compared with younger (0–4 years) and pubertal (13–18 
years) children. 
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Study design: We retrospectively (2002–2016) identified patients <18 years with surgery for 
primary testicular tumor. Patients with testicular tumor risk were excluded. Ultrasound 
studies were reviewed for contralateral testis volume, tumor morphology, and tumor maximal 
diameter, for three age groups: 0–4, 5–12, and 13–18 years. The Freeman-Halton extension 
of the Fisher exact probability test was adopted for categorical outcomes, and one-way 
ANOVA for continuous outcomes. 
Results: Fifty-two patients (mean age 11.0 years, range 6 days to 18 years) were identified. 
Malignant tumor prevalence significantly differed (p<0.01) among age groups (Fig.): 0–4 
(72.7%, 8/11), 5–12 (0%, 0/16), and 13–18 years (44.0%, 11/25). The most common tumor 
types in 5–12 years were epidermoid cyst (31.3%, 5/16) and tumor mimics (37.5%, 6/16). 
Prevalence of cystic tumors in 5–12 year olds was not significantly different compared with 
other age groups. Contralateral testicular volume >4 mL (pubertal surge) significantly 
(p<0.01) differed among groups: 0–4 years (0/11), 5–12 years (3/16), and 13–18 years 
(19/20). In children aged 13–18 years the mean tumor maximal diameter (29.8±4.4 mm) was 
significantly larger (p<0.01) compared with children 5–12 years (9.3±5.5 mm) and all 
malignant tumors had contralateral testicular volume >4 mL. 
Discussion: We found that preadolescent children between the ages of 5 and 12 years have 
distinctive characteristics compared with the other age groups. Most importantly, no 
malignant testicular tumors were found in this age group. About a third of the children 
presented with an incidental testicular mass. The testicular tumors were significantly smaller 
(9.3±6.7 mm) compared with those in children aged 13–18 years (29.8±4.4 mm). There were 
limitations because of the retrospective nature of the study. 
Conclusion: We found no malignant testicular tumors in children aged 5 to 12 years with no 
risk factors and prior to pubertal surge. Our study suggests use of more conservative 
treatment in this group of patients. 
Figure. Contralateral testicular volume in children with benign and malignant testicular 
tumors. 
Introduction 
Testicular tumors in children have a bimodal age distribution: one peak occurs at age 2–4 
years, and the second occurs at age 15–18 years [1,2]. The clinical consideration in these two 
age periods is quite different and thus therapy varies as well. 
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In prepubertal boys younger than 5 years, testicular tumors are different from adult 
neoplasms. Germ cell tumors are less common than in adults and account for 60–77% of the 
testicular tumors [3–6]. The most common germ cell tumors are teratoma and yolk sac 
tumors. Prepubertal teratomas are all benign and most yolk sac tumors present as clinical 
stage I. About a third of the tumors are benign gonadal stromal tumors including Sertoli cell 
tumors, juvenile granulosa cell tumors, and Leydig cell tumors [3–6]. Therefore, when 
possible, testicular-sparing surgery should be considered. 
In pubertal boys, most germ cell tumors are malignant; the most common types are 
mixed germ cell tumors. Radical orchiectomy is both diagnostic and therapeutic. Treatment 
with chemotherapy depends on histology and the stage of tumor. The initial therapy for 
metastatic or retroperitoneal disease is multi-agent chemotherapy. Retroperitoneal dissection 
is performed for residual or nonresponsive disease in the retroperitoneum. If there are no 
radiographic nodes at presentation, then surveillance, staging retroperitoneal dissection, or 
chemotherapy are options [7]. 
However, between these two age peaks, little is known about the nature of testicular 
tumors presenting in prepubertal boys after the age of 5 years. Such knowledge is needed to 
choose among markedly different treatment strategies. In this study, we compared the clinical 
presentation, ultrasound findings, tumor pathology, and treatment in 5–12 year olds compared 
with other age groups. We wanted to know if there are any distinctive characteristics of 
tumors in this age group that can help in patient management. 
Materials and methods 
This HIPAA-compliant study was approved by our institutional review board, with waiver of 
informed consent. From the pathology archive at our institution, we retrospectively identified 
all pediatric patients who underwent biopsy or surgical resection of ultrasound-diagnosed 
primary testicular tumor, during a 15-year (2002–2016) period. Only children who were 
treated at our institution were included. Results from outside consultations were excluded. 
We also excluded patients with an underlying risk for testicular tumors (e.g., congenital 
adrenal hyperplasia, Peutz-Jeghers syndrome, mixed gonadal dysgenesis, testosterone 
insensitivity syndrome), and testicular tumors found in children who had orchiectomy of 
undescended atrophic testis. 
Medical records were reviewed for epidemiologic data, clinical presentation, levels of 
alpha fetoprotein (AFP), and beta human chorionic gonadotropin (hCG). Normal values of 
AFP and hCG levels by age were used as a reference [8,9]. From the pathology report, we 
retrieved the final diagnosis and whether the tumor was malignant or benign. Using the 
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ultrasound studies, we evaluated the maximal diameter of the tumor, echotexture, presence of 
calcifications in the tumor, and presence of microlithiasis. Testicular masses were categorized 
as follows: solid, cystic (cystic mass without any solid component), and complex (contain 
both solid and cystic component). When images from ultrasound studies were not available 
for review, we retrieved the information from the report. As the testicular mass may change 
overall testicular volume, we evaluated the volume of the contralateral testis from ultrasound 
performed before surgery as follows: length × height × width × 0.52 [10]. 
Descriptive statistics (means and standard deviations (SD), frequencies) were 
calculated for patient tumor characteristics. We compared tumor characteristics among three 
age groups (0–4 years, 5–12 years, and 13–18 years). The Freeman-Halton extension of the 
Fisher exact probability test was adopted for categorical outcomes, and one-way ANOVA for 
continuous outcomes. One-way repeated measures ANOVA was used for assessing the 
difference between mean tumor diameters as one patient had bilateral tumors. A post-hoc test 
was performed to examine specific differences across groups. A p-value less than 0.05 was 
considered to be significant. 
Results 
The study group included 52 children with an age range of 6 days to 18 years (mean 11.0 
years). Eleven children were aged 0–4 years, 16 were aged 5–12 years, and 25 were aged 13–
18 years. There was a significant difference in prevalence of the different types of clinical 
presentation between those aged 5-12 years and other age groups (p<0.02, Table 1). Nine 
patients had incidental non-palpable testicular mass and had scrotal US for evaluation of 
contralateral testicular pain (n=4), non-localized scrotal discomfort/pain (n=2), evaluation of 
varicocele (n=1), post-orchiopexy evaluation (n=1), and ecchymosis on the scrotum in a child 
with Henoch-Schonlein purpura (n=1). Incidental non-palpable testicular mass was most 
common in the 5–12 age group (6/16, 37.5%), but the difference was not significant 
compared with age 0–4 (0/11, 0%, p=0.22), and age 13–18 (3/25, 12.0%, p=0.12), after 
multiple testing correction. Only one child (age 11.4 years) had a history of orchiopexy for 
undescended testis. Laboratory results of AFP and hCG were available in 49/52 (94.2%) of 
the patients. None of the patients in the age group of 5-12 years had elevated AFP or hCG 
compared with 7/49 (14.3%) patients with elevated AFP and 8/49 (16.3%) elevated hCG in 
the other age groups (Table 1). 
Ultrasound 
Of the preoperative ultrasound studies, 48/52 (92.3%) were available for review; in four other 
patients the information was retrieved from the reports. There was no significant difference in 
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prevalence of cystic tumors in children aged 5–12 years (5/16, 31.3%) compared with the 
other age groups (0/11, 0%, p=0.08, for age 0–4 and 10/25, 40.0%, p=0.12 for age 13–18). 
The testicular tumor maximal diameter was available in 51 patients. The mean tumor 
maximal diameter was significantly smaller (p=0.01) in patients in the 5–12 year age group 
(9.3±5.5 mm), compared with children aged 13–18 years (29.8±4.4 mm), but not significantly 
different (p=0.44) from children aged 0–4 years (20.3±6.9 mm). 
As expected, mean contralateral testicular volume was significantly (p<0.01, Table 1) 
different among the three age groups (summary Figure), ranging from 0.6±0.3 mL at 0–4 
years to 2.6±2.2 mL at age 5–12 years and 12.0±6.0 mL at age 13–18 years. The presence of 
a contralateral testicular size > 4 mL was also significantly (p<0.01) different among groups, 
ranging from 0/10 (0%) at 0–4 years to 3/16 (18.8%) at 5–12 years and 21/22 (95.4%) at 13–
18 years. In children aged 13–18 years with malignant tumors, the smallest testicular volume 
was 5.9 mL. Ultrasound of the contralateral testis was not available for review in four 
patients. 
Preoperative ultrasound was not available for review in one pubertal patient, a 17.6 
year old with mixed germ cell tumor. The contralateral testicular volume measured from a 
CT of the abdomen performed to evaluate for retroperitoneal metastatic lymph nodes was 
25.3 mL, based on the same method described for the ultrasound. 
Pathology 
There was a significant (p<0.01, Table 1) difference among the prevalence of malignant 
tumors in the age group of 5–12 years (no malignant tumors) compared with 63.6% (7/11) at 
0–4 years and 44.0% (11/25) at 13–18 years (Table 2). 
For age 5–12 years, the most common tumor was epidermoid cysts (n=5). There were 
seven benign conditions mimicking a tumor: Leydig cell nodular hyperplasia (n=3, Fig. 1), 
Sertoli cell nodule (n=1), and mixed stages of testicular maturation (n=3, Fig. 2). Most (4/7, 
57.1%) of the benign conditions had a maximal diameter of less than 5 mm by ultrasound. 
The malignant tumors for age 0–4 years were juvenile granulosa cell (n=4), and yolk 
sac tumor (n=3), and the most common benign tumor was teratoma (n=3). In patients aged 
13–18 years, the most common malignant tumors were germ cell tumors (n=11), eight of 
which were mixed germ cell tumors. The malignant tumor with the smallest maximal 
diameter was 7 mm by ultrasound. Three of the germ cell tumors were metastatic. The most 
common benign tumor was epidermoid cyst (n=10). 
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None of the 14 children 5 years or older with contralateral testicular volume <4 mL 
had malignant testicular tumor, while 10/24 (41.7%) of these children with testicular volume 
≥4 mL had malignant tumor (p<0.01). 
Treatment 
Table 1 summarizes the treatment for testicular masses. Of the group aged 5–12 years, 11/16 
(68.8%) underwent testicular-sparing surgery. This did not significantly differ after multiple 
testing adjustments from the 0–4 year group (2/11, p=0.05) or the 13–18 year group (10/25, 
p=0.33). 
Discussion 
Prepubertal testicular tumors are rare, with an incidence of 1-2% of all pediatric solid tumors 
and occurring at an incidence of 0.5 to 2/100,000 children [4,5]. There is little literature on 
preadolescent children after the first peak of testicular tumors at the age of 2–4 years and 
before the second peak of testicular tumors in postpubertal boys after the age of 15 years 
[1,2]. In this study we summarized the unique clinical, imaging, and pathology characteristics 
of this group of patients at the age range of 5–12 years. Our findings in this age group are 
further validated by our findings in younger and older children, which are similar to 
previously published series. In our study, in patients under the age of 5, 36.4% (4/11) of the 
tumors were benign, which is comparable with prior publications indicating that a third to 
half of these tumors are benign [3–5,11]. In patients between 13 and 18 years in our series, 
11/25 (44.0%) of the tumors were malignant; the most common was mixed germ cell tumor 
(8/11, 72.7%). This is consistent with a reported peak incidence of malignant testicular 
tumors in adolescents of 15–19 years [12]. 
We found that preadolescent children between ages 5 and 12 years with testicular 
masses have unique characteristics that were significantly different compared with the other 
age groups. About a third of the children presented with an incidental testicular mass. No 
child had elevated tumor markers (AFP or hCG). The testicular tumors were significantly 
smaller (9.3±6.7 mm) compared with 29.8±4.4 mm in children aged 13–18 years. Most 
importantly, in this group all tumors were benign. Malignant testicular tumors have been 
rarely reported in this age group. In a prepubertal registry in Korea, 209 testicular tumors 
were identified in 87 hospitals during a period of 5 years. Seven of the 100 yolk sac tumors 
were diagnosed at age 4-8 years and two cases of mixed germ cell tumors at age 8-10 years 
[4]. In a registry of testicular tumors on preadolescent boys 12 years and younger, 98 patients 
were found in four large tertiary children’s hospitals in a period of time that ranged from 11 
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to 25 years [3]. There were no details on tumor distribution per age. None of these patients 
had seminoma or mixed germ cell tumor. 
There are no details on the presentation, ultrasound findings, and pubertal stage in 
these studies. 
Ultrasound characteristics of the tumor were only helpful in the preoperative 
diagnosis of epidermoid tumor as all had the typical onion ring appearance. All other masses 
had nonspecific findings. It is of interest that seven of the 16 children aged 5–12 years had 
benign conditions mimicking a tumor on ultrasound. These benign conditions included 
nodular hyperplasia of Leydig cells (n=3), Sertoli cells nodule (n=1), and mixed stages of 
testicular maturation (n=3). Nodular hyperplasia of Leydig cells is rare in children and was 
described in several case reports in children presenting with precocious puberty [13–15]. 
Leydig cell hyperplasia was not described as an incidental mass in prepubertal boys. It is 
possible that elevated luteinizing hormone at the start of puberty rarely causes nodular 
hyperplasia of Leydig cells. Mixed stages of testicular maturation can also be a result of the 
early stages of puberty. Sertoli cell nodules, also called Pick’s adenoma, are usually found 
incidentally in the testis and only rarely produce symptoms [16]. This has not been described 
before as presenting as a testicular nodule. It is possible that with the increased use of scrotal 
ultrasound there is increased identification of incidental benign non-palpable testicular 
lesions [17,18]. 
There is a clear relationship between development of malignant germ cell tumors and 
stage of puberty. In a study on risk stratification of pubertal children and postpubertal 
adolescents (21 years and younger) with clinical stage I testicular nonseminomatous germ 
cell tumors, 23 patients were identified. Pathologic high-risk germ cell tumors were found 
only in patients with Tanner stages 4 and 5 [7]. Our study suggests that in prepubertal boys at 
the period of time that the hypothalamic pituitary axis is blocked, there is a very low risk for 
malignant transformation. It is therefore important to consider not only the age group but also 
the stage of puberty. The beginning of puberty is marked by testicular growth. A testicular 
volume of 4 mL was taken as the indication of onset of puberty [19]. This has been supported 
by studies [11–14] that show a testicular volume of 4 mL is achieved just before the stage of 
the testicular growth spurt. In our study we found that 88.9% of the boys in the age group of 
5–12 years had a contralateral testicular volume of less than 4 mL, and that the smallest 
testicular volume in the age group of 13–18 years with testicular cancer was 5.9 mL. 
Our experience and evidence from other studies showing a low malignancy rate in 
children aged 5-12 years with testicular tumors suggest that in this group of patients, when 
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tumor markers are negative, a conservative approach should be considered. Rather than using 
an upper age limit of 12 years, evidence of pubertal Tanner stage 2 or lower, or contralateral 
testicular volume of less than 4 mL may be better selection criteria. In our case series, all of 
the 14 patients older than 5 years with contralateral testicular volume less than 4 mL had a 
benign testicular mass. Most (57.1%) of the testicular tumor mimickers had a diameter of less 
than 5 mm. Therefore, in some prepubertal children with a small (maximal diameter <5mm) 
incidental non-palpable testicular mass, follow-up ultrasound should be considered rather 
than a biopsy. There are studies that suggest that the use of contrast enhanced ultrasound can 
help with this conservative approach if no vascularity is identified in the testicular mass [20]. 
Our study has a few limitations because of the relatively small number of patients, the 
retrospective nature of the study, and selective bias as our institution is a referral medical 
center for testicular tumors. One other limitation is that four patients did not have 
preoperative ultrasound for review. Three of these patients were older than 5 years; only one 
of them (age 17.6 years) had a malignant tumor with contralateral testicular volume of 25.3 
mL measured from the abdominal CT scan. 
Conclusion 
In summary, among prepubertal children older than 5 years with a testicular mass on 
ultrasound and without preexisting risk factors, we found no malignant tumors. Based on our 
experience, we suggest consideration of a more conservative approach to this group of 
patients, with only ultrasound follow-up for selected small non-palpable masses, and strong 
consideration for testicular-sparing surgery if biopsy is negative for malignant tumor. 
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Table 1. Characteristics of 52 children with testicular masses categorized into three age 
groups: 0–4 years, 5-12 years, and 13–18 years 
Age group <5 years 
(N=11) 
5–12 years 
(N=16) 
13–18 years 
(N=25) 
p-
value 
Presentation    0.02 
Mass 11 (100%) 8 (50%) 16 (64.0%)  
EPain 0 2 (12.5%) 6 (24.0%)  
Incidental 0 6 (37.5%) 3 (12.0%)  
Ultrasound morphology    <0.01 
Solid 2 (18.8%) 8 (50.0%) 10 (40.0%)  
Cystic 0 5 (31.3%) 10 (40.0%)  
Complex 9 (81.8 %) 3 (18.8%) 5 (20.0%)  
Mean size of tumor± SD (mm) 20.3±6.9 9.3±5.5 29.8±4.4 0.02 
Mean size of contralateral 
testis± SD (mL) 0.6±0.3 2.6±2.2 12.0±6.0 <0.01 
Tumor markers     
Elevated AFP 4 (36.4%) 0 3 (30%) 0.02 
Elevated hCG 1 (12.5%) 0 7 (87.5%) 0.02 
Pathology    <0.01 
Benign 4 (36.4%) 16 (100%) 14 (56.0%)  
Malignant 7 (63.6%) 0 11 (44.0%)  
Surgical intervention    0.03 
Radical orchiectomy 9 (81.8%) 5 (31.2%) 15 (60.0%)  
Testis-sparing surgery 2 (18.2%) 11 (68.8%) 10 (40.0%)  
AFP = alpha fetoprotein; hCG = human chorionic gonadotropin. 
 
Table 2. Clinical, ultrasound, and pathologic findings in children aged 5–12 years with 
testicular mass 
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Pati
ent 
num
ber 
Ag
e, 
ye
ars 
Present
ation 
Testi
cle 
Tum
or 
Surg
ery 
     
   Side Volu
me 
(mL)
a
 
ML
T 
Siz
e 
(m
m) 
Characterist
ics 
Vascul
arity 
Patholo
gy 
 
1 5.0 Inciden
tal 
RT 1.1 No 9 Cyst + 
“onion 
rings” 
No Epider
moid 
cyst 
TSS 
2 5.8 Mass RT 0.6 No 28 Cyst 
+calcificatio
n 
Increas
ed at 
the rim 
Benign 
Sertoli 
cell 
tumor 
Orchiec
tomy 
3b 6.1 Mass RT 2.8 No 22 Cyst, 
lamellate 
No Cystic 
dysplasi
a  
Orchiec
tomy 
4 7.7 Mass LT 0.6 No 4 Hypoechoge
nic 
Norma
l 
Leydig 
cell 
hyperpl
asia 
TSS 
5 8.0 Inciden
tal 
LT 2.2 Yes 6.7 Peripheral 
hyperechog
enicity 
Norma
l 
Leydig 
cell 
hyperpl
asia 
 TSS 
6 9.0 Inciden
tal 
RT 1.6 No 7.5 Peripheral 
hyperechog
enicity 
Increas
ed 
Benign 
Leydig 
cell 
tumor 
Orchiec
tomy 
7 10.
1 
Mass LT 1.0 No 7 Cyst + 
“onion 
rings” 
No Epider
moid 
cyst 
TSS 
8 10.
3 
Inciden
tal 
LT  2.2 No 4 Hypoechoic 
rim + 
microcalcifi
cationsc 
No Pick’s 
adenom
a 
TSS 
9 10.
7 
Pain LT 2.3 No 4.8 Hypoechoge
nic rim 
Increas
ed 
Capillar
y 
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MLT = microlithiasis; RT = right; LT = left; TSS = testicular-sparing surgery. 
a
 Contralateral testicular volume. 
b
 Findings in patient 3 were based on ultrasound report. 
c
 Microcalcifications confined to the mass. 
 
 
Figure 1. An island of immature testis mimicking a mass in an 11.8-year-old boy who 
presented with left testicular pain. (A) Transverse ultrasound demonstrates an echogenic 
nodule (arrow). (B), (C) Post orchiectomy hematoxylin and eosin staining pathology slides 
demonstrate an island of immature testis surrounded by tissue with more developed 
spermatogenesis (arrow (B), magnification of 1.25, arrowheads (C) magnification of 4). 
Figure 2. An 8-year-old presented with intermittent left testicular swelling. (A) Longitudinal 
ultrasound demonstrates a testicular nodule with thick echogenic rim associated with 
microlithiasis. (B) Post-biopsy hematoxylin and eosin staining pathology slides demonstrate 
an island of Leydig cell nodular hyperplasia (arrow, magnification 1.25). 
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